Going forward, particularly as emerging data suggest that those with NAFLD-HCC may be less likely to respond to agents inhibiting PD-1/PD-L1 [61], understanding the immune environment is essential, as is identifying clinically useful tissues and blood-based biomarkers. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.